Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
United Therapeutic
(NQ:
UTHR
)
274.26
+2.04 (+0.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about United Therapeutic
< Previous
1
2
3
4
5
6
7
Next >
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
August 03, 2022
From
United Therapeutics Corporation
Via
Business Wire
Earnings Outlook For United Therapeutics
August 02, 2022
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that United...
Via
Benzinga
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
July 27, 2022
From
United Therapeutics Corporation
Via
Business Wire
7 Best Pharmaceutical Stocks to Buy Now
July 20, 2022
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.
Via
InvestorPlace
Swing Trading Stock Watchlist For The Week Of July 11 And Beyond
July 09, 2022
The stock market's health is improving, but a likely bottom has not been confirmed yet. That means I’m buying some stocks (swing trades), but I'm not loading up yet. Let's see what I'm looking at.
Via
Talk Markets
Expert Ratings for United Therapeutics
May 24, 2022
Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings:
Via
Benzinga
7 Biotech Stocks With Key Catalysts Coming in July
June 27, 2022
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.
Via
InvestorPlace
Buy These 3 Low-Beta Stocks To Sail Through A Choppy Market
June 25, 2022
Creating a portfolio of low-beta stocks is of utmost importance since the securities will deliver healthy returns and provide a shield against volatile market conditions.
Via
Talk Markets
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
June 23, 2022
The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year.
Via
Investor's Business Daily
Will Investors Notice Exciting Sign On United Therapeutics's Chart?
June 10, 2022
If history is any guide, there may be good fortune ahead for shares of United Therapeutics (NASDAQ:UTHR). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish...
Via
Benzinga
United Therapeutics Provides an Update on Its Organ Printing Programs
June 06, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
June 03, 2022
From
United Therapeutics Corporation
Via
Business Wire
Short Volatility Alert: United Therapeutics Corporation
May 26, 2022
On Wednesday, shares of United Therapeutics Corporation (NASDAQ: UTHR) experienced volatile short activity. After the activity, the stock price went up 4.31% to $228.39. The...
Via
Benzinga
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot'
May 24, 2022
United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier.
Via
Investor's Business Daily
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
May 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
United Therapeutics Announces FDA Approval of Tyvaso DPI™
May 24, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics's Return on Invested Capital Insights
May 18, 2022
According to Benzinga Pro, during Q1, United Therapeutics (NASDAQ:UTHR) earned $239.90 million, a 113.81% increase from the preceding quarter. United Therapeutics also posted a total of $461.90 million...
Via
Benzinga
7 Biotech Stocks With Key Catalysts for May
May 11, 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.
Via
InvestorPlace
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Recap: United Therapeutics Q1 Earnings
May 04, 2022
United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
May 04, 2022
From
United Therapeutics Corporation
Via
Business Wire
Earnings Scheduled For May 4, 2022
May 04, 2022
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Via
Benzinga
Earnings Outlook For United Therapeutics
May 03, 2022
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that United...
Via
Benzinga
United Therapeutics Q1 2022 Earnings Conference Call On May 4, 2022 At 09:00 AM ET
April 29, 2022
United Therapeutics (NASDAQ:UTHR) will host a conference call at 09:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend United Therapeutics (UTHR) Conference Call Follow this...
Via
Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
April 29, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
April 27, 2022
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
April 06, 2022
From
United Therapeutics Corporation
Via
Business Wire
First Human With Pig Heart Transplant Dies: Reuters
March 09, 2022
A 57-year-old man with terminal heart disease who became the first person to receive a genetically modified pig's heart has died, the University of Maryland Medical...
Via
Benzinga
10 Biggest Price Target Changes For Monday
February 28, 2022
Barclays cut the price target on MasTec, Inc. (NYSE: MTZ) from $140 to $120. MasTec shares fell 0.1% to $79.00 in pre-market trading.
Via
Benzinga
Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease
February 28, 2022
PH-ILD is a rare, serious, and progressive illness without an approved treatment in Europe and many other parts of the world
Via
Newswire.com
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.